Axsome Therapeutics, Inc. (AXSM): Price and Financial Metrics
GET POWR RATINGS... FREE!
AXSM Stock Price Chart Interactive Chart >
AXSM Price/Volume Stats
|Current price||$37.96||52-week high||$71.50|
|Prev. close||$37.03||52-week low||$19.38|
|Day high||$39.73||Avg. volume||1,125,397|
|50-day MA||$29.27||Dividend yield||N/A|
|200-day MA||$32.97||Market Cap||1.48B|
Axsome Therapeutics, Inc. (AXSM) Company Bio
Axsome Therapeutics Inc. focuses on developing therapies for the management of pain, neurological disorders, and other central nervous system. The company was founded in 2012 and is based in New York City, New York.
Most Popular Stories View All
AXSM Latest News Stream
|Loading, please wait...|
AXSM Latest Social Stream
View Full AXSM Social Stream
Latest AXSM News From Around the Web
Below are the latest news stories about Axsome Therapeutics Inc that investors may wish to consider to help them evaluate AXSM as an investment opportunity.
The FDA accepts Bristol Myers' (BMY) sBLA for Breyanzi under a priority review as a second-line treatment for relapsed/refractory large B-cell lymphoma. A decision is due on Jun 24, 2022.
Axsome to host conference call and webcast on Tuesday, March 1, 2022 at 8:00 AM Eastern Time
NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a virtual fireside chat at the 11 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16, 2022 at 1:40 PM Eastern Time.
Although home run stocks, or equities capable of producing life-altering returns in a short period of time, are far from commonplace, the biopharmaceutical industry has been fertile ground for explosive growth vehicles for a number of years now. While developing pharmaceuticals is fraught with risk at nearly every step, several clinical-stage biotechs have, in fact, overcome these long odds over the past 10 years to bring important new medicines to market. Investors, in turn, ought not overlook the extraordinary risks associated with potential home run plays in the complex world of biopharmaceuticals.
Deciphera (DCPH) reports wider-than-expected loss in the fourth quarter while revenues beat estimates. Stock down is after-hours trading.
AXSM Price Returns